

Quarterly Statement Q3 2025

December 1, 2024 to August 31, 2025

Contents

2	Key Figures
3	Revenue, Adjusted EBITDA and Free Cash Flow
5	Forecast 2025
6	Financial Information
11	Additional Information

Key Figures

In EUR m	Q3 2025	Q3 2024	Change in %		9M 2025	9M 2024	Change in %	
			Actual	Organic			Actual	Organic
Results of operations								
Revenues	560.7	498.5	12.5	–	1,681.4	1,467.0	14.6	–
Adjusted EBITDA	103.4	104.4	–1.0	–	313.9	292.7	7.2	–
Adjusted EBITDA margin in %	18.4	21.0	–260bps	–	18.7	20.0	–130bps	–
Revenues (organic) ¹⁾	576.2	583.4	–	–1.2	1,705.3	1,737.2	–	–1.8
Adjusted EBITDA (organic) ¹⁾	108.1	119.4	–	–9.4	320.7	346.6	–	–7.5
Adjusted EBITDA margin in % (organic) ¹⁾	18.8	20.5	–	–170bps	18.8	19.9	–	–110bps
Adjusted net income ²⁾	24.4	40.6	–39.8	–	72.3	107.1	–32.5	–
Earnings per share in euros ³⁾	–0.37	0.79	>–100.0	–	–0.40	2.10	>–100.0	–
Adjusted EPS in euros ⁴⁾	0.69	1.16	–40.5	–	2.05	3.06	–33.0	–
Adjusted EPS in euros (currency-adjusted) ⁴⁾	0.77	1.20	–	–35.8	2.16	3.20	–	–32.5
Financial position								
Cash flow from operating activities	85.5	71.3	20.0	–	119.8	106.5	12.5	–
Cash-effective capital expenditure	–67.8	–82.1	17.4	–	–250.4	–279.9	10.5	–
Cash flow from investing activities	–65.0	–76.1	14.5	–	–594.4	–268.7	>–100.0	–
Free cash flow before M&A activities	20.5	–4.8	>100.0	–	–118.8	–152.8	22.3	–

In EUR m	Aug. 31, 2025	Nov. 30, 2024	Change in %	
			Actual	Organic
Net assets position				
Total assets and total liabilities	4,686.8	3,809.2	23.0	–
Equity	1,427.8	1,539.1	–7.2	–
Equity ratio in %	30.5	40.4	–990bps	–
Net working capital (reporting date)	336.5	232.7	44.6	–
Net financial debt	2,015.9	1,100.3	83.2	–
Adjusted EBITDA leverage ⁶⁾	4.15	2.43	–	–
Employees				
Employees (reporting date)	13,535	12,142	11.5	–

¹⁾ Organic revenue and organic adjusted EBITDA include the revenue and adjusted EBITDA of Bormioli Pharma in both 2024 and 2025, which we acquired on December 10, 2024 and fully consolidate from the beginning of the financial year 2025, translated at the budgeted exchange rates for the financial year 2025.

²⁾ Adjusted net income: Net income before depreciation/amortization/impairment losses of fair value adjustments less capitalized cost components, and restructuring expenses, as well as before the balance of exceptional income and expenses and the related tax effects.

³⁾ Earnings per share in euros: Earnings per share attributable to shareholders of Gerresheimer AG, based on 34.540m shares.

⁴⁾ Adjusted EPS in euros: Adjusted earnings per share attributable to shareholders of Gerresheimer AG, based on 34.540m shares.

⁵⁾ Based on adjusted EPS in euros excluding the earnings contributions of Bormioli Pharma for Q3 2024 and 9M 2024, translated at the budgeted exchange rates for the financial year 2025, based on 34.540m shares.

⁶⁾ Adjusted EBITDA leverage: The relation of net financial debt to adjusted EBITDA of the last twelve months according to the credit agreement currently in place.

Revenues, Adjusted EBITDA and Free Cash Flow

Plastics & Devices

In EUR m	Q3 2025	Q3 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	324.0	278.6	16.3	2.5
Adjusted EBITDA	71.5	70.4	1.7	-7.0
Adjusted EBITDA margin in %	22.1	25.3	-320bps	-230bps

In EUR m	9M 2025	9M 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	972.6	820.1	18.6	2.6
Adjusted EBITDA	222.6	208.5	6.8	-6.6
Adjusted EBITDA margin in %	22.9	25.4	-250bps	-230bps

¹⁾ The revenues of the divisions include intercompany revenues.

Revenues in the Plastics & Devices Division amounted to EUR 972.6m in the first nine months of the financial year 2025, compared to EUR 820.1m in the same period of the prior year, which reflects an increase of 18.6%. The increase is primarily due to the first-time inclusion of the revenue contribution from Bormioli Pharma. Taking into account the revenue of Bormioli Pharma in the period from December 2023 to August 2024 and adjusted for foreign exchange rate effects, revenues increased by 2.6% compared to the prior-year period. The exchange rate effects resulted mainly from the change in the US dollar against the euro. The high demand for drug delivery systems compensated for the temporary market weakness in plastic containment solutions for oral liquids.

Adjusted EBITDA was up by 6.8% and organically down by 6.6% compared to the same period in the prior year. The organic adjusted EBITDA margin of 22.9% reflects lower capacity utilization at Oral Liquids due to lower market demand as well as start-up costs for the ramp-up of new production lines and lower capacity utilization during the start-up phase for drug delivery systems.

Primary Packaging Glass

In EUR m	Q3 2025	Q3 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	239.6	221.5	8.2	-5.5
Adjusted EBITDA	42.0	45.4	-7.6	-13.8
Adjusted EBITDA margin in %	17.5	20.5	-300bps	-170bps

In EUR m	9M 2025	9M 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	714.4	648.0	10.3	-6.9
Adjusted EBITDA	127.2	119.7	6.2	-7.2
Adjusted EBITDA margin in %	17.8	18.5	-70bps	-

¹⁾ The revenues of the divisions include intercompany revenues.

In the Primary Packaging Glass Division, revenues of EUR 714.4m were generated in the first nine months of the financial year, after EUR 648.0m in the prior-year period. This increase of 10.3% is primarily due to the first-time inclusion of the revenue contribution from Bormioli Pharma. Taking into account the revenue of Bormioli Pharma in the period from December 2023 to August 2024 and adjusted for foreign exchange rate effects, revenues in the first nine months of the financial year 2025 were 6.9% lower than in the same period of the prior year. The exchange rate effects resulted mainly from the change in the US dollar against the euro.

The organic decline in sales was caused, among other things, to continued subdued demand in the cosmetics business and in the oral liquid business in the pharmaceuticals sector. Among others, demand for our Gx® RTF vials developed positively.

Adjusted EBITDA increased by 6.2%, respectively decreased organically by 7.2% compared to the first nine months of the prior year. The decline in adjusted EBITDA is primarily attributable to a decrease in demand in the Moulded Glass Business Unit. The adjusted EBITDA margin decreased by 70 basis points to 17.8%, after 18.5% in the same period of the prior year. The organic adjusted EBITDA margin remained unchanged at 18.0% (9M 2024: 18.0%).

Advanced Technologies

In EUR m	Q3 2025	Q3 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	1.1	1.4	-20.4	-20.4
Adjusted EBITDA	-4.1	-5.0	17.5	18.7
Adjusted EBITDA margin in %	-	-	-	-

In EUR m	9M 2025	9M 2024	Change in %	
			Actual	Organic
Revenues ¹⁾	3.9	4.1	-6.5	-6.5
Adjusted EBITDA	-12.3	-13.6	9.2	10.7
Adjusted EBITDA margin in %	-	-	-	-

¹⁾ The revenues of the divisions include intercompany revenues.

At EUR 3.9m, revenue in the Advanced Technologies Division in the first nine months of the financial year 2025 was on a par with the same period of the prior year. Adjusted EBITDA improved year on year to EUR -12.3m.

The division's development projects, amongst them digital platforms for therapy support, wearable medication pumps for small- and large-molecule drugs, and the proprietary auto-injector platform, are continuing as planned.

Reconciliation of Adjusted EBITDA

In EUR m	Q3 2025	Q3 2024	Change in %	
			Actual	Organic
Plastics & Devices	71.5	70.4	1.7	-7.0
Primary Packaging Glass	42.0	45.4	-7.6	-13.8
Advanced Technologies	-4.1	-5.0	17.5	18.7
Corporate functions/consolidation	-6.0	-6.4	6.1	-
Adjusted EBITDA	103.4	104.4	-1.0	-9.4

In EUR m	9M 2025	9M 2024	Change in %	
			Actual	Organic
Plastics & Devices	222.6	208.5	6.8	-6.6
Primary Packaging Glass	127.2	119.7	6.3	-7.2
Advanced Technologies	-12.3	-13.6	9.6	10.7
Corporate functions/consolidation	-23.6	-21.9	-7.8	-
Adjusted EBITDA	313.9	292.7	7.2	-7.5

Free Cash Flow

In EUR m	Q3 2025	Q3 2024	Change
Cash flow from operating activities	85.5	71.3	14.2
Net capital expenditure before M&A activities	-65.0	-76.1	11.1
Free cash flow before M&A activities	20.5	-4.8	25.3

In EUR m	9M 2025	9M 2024	Change
Cash flow from operating activities	119.8	106.5	13.3
Net capital expenditure before M&A activities	-238.6	-259.3	20.7
Free cash flow before M&A activities	-118.8	-152.8	34.0

In the first nine months of the current financial year, cash flow from operating activities amounted to EUR 119.8m, compared to EUR 106.5m in the same period of the prior year. The adjusted EBITDA for the first nine months was higher than in the same period of the prior year. Lower funds locked up in net working capital compared with the same period of the prior year had a positive effect on cash flow from operating activities. Interest payments on variable-rate debt, which rose compared with the same period of the prior year, reduced cash flow from operating activities. Taking into account the above-mentioned effects and net capital expenditure, free cash flow before M&A activities amounted to EUR -118.8m as of August 31, 2025, compared to EUR -152.8m in the same period of the prior year.

Net capital expenditure in the first nine months of the financial year includes payments from government grants in the amount of EUR 9.3m (9M 2024: EUR 18.4m).

Capital expenditure in the Plastics & Devices Division focused on the further expansion of syringe capacities in Germany, Mexico, and the Republic of North Macedonia, as well as the expansion of capacity for plastics products and medical systems in North America.

In the Primary Packaging Glass Division, capital expenditure mainly related to the construction of a new furnace at the Lohr site (Germany) and capacity expansions for injection vials in Morganton (NC/USA).

Forecast 2025

Based on the course of business to date, the company now expects the following development for the 2025 financial year:

Key performance indicator	Basis	Adjusted Forecast 2025 ⁴⁾	Adjusted Forecast 2025
Revenues	EUR 2,400.0m ¹⁾	Organic growth between 0% and 2%	Organic decline between -4% to -2%
Adjusted EBITDA margin	-	Around 20% (currency-adjusted)	Around 18.5% to 19% (organic)
		Decline in the low-double-digit percentage range (currency-adjusted) ³⁾	Decline in the mid-double-digit percentage range (currency-adjusted)
Adjusted EPS in euros	EUR 4.85 ²⁾		

¹⁾ Based on the revenues for the financial year 2024, including revenues of Bormioli Pharma, translated at the budgeted exchange rates for the financial year 2025.

²⁾ Based on adjusted EPS for the financial year 2024, excluding the earnings contributions of Bormioli Pharma, translated at the budgeted exchange rates for the financial year 2025, based on 34.540m shares.

³⁾ High single-digit percentage range is the range between 7 and 9%.

⁴⁾ Adjusted forecast as of July 10, 2025.

Duesseldorf (Germany), October 10, 2025

The Management Board

Financial Information

for the third quarter and the first nine months of the financial year 2025

Net financial debt

In EUR m	Aug. 31, 2025	Nov. 30, 2024	Change
Promissory loans – November 2015 (nominal)	25.5	25.5	–
Promissory loans – September 2017 (nominal)	45.5	45.5	–
Promissory loans – November 2020 (nominal)	162.0	162.0	–
Promissory loans – November 2021 (nominal)	75.0	75.0	–
Promissory loans – November 2022 (nominal)	300.0	300.0	–
Promissory loans – October 2024 (nominal)	600.0	600.0	–
Revolving credit facilities	102.0	–	102.0
Bridge loan acquisition Bormioli Pharma	725.0	–	725.0
Local credit facilities and overdraft facilities	36.1	8.7	27.4
Liabilities from lease, factoring and installment purchases	90.7	70.0	20.7
Financial debt	2,161.8	1,286.7	875.1
Cash and cash equivalents	145.9	186.4	–40.5
Net financial debt	2,015.9	1,100.3	915.6

Capital structure

In % of total assets	Aug. 31, 2025	Nov. 30, 2024
Non-current assets	76.8	73.9
Current assets	23.2	26.1
Equity	30.5	40.4
Financial debt	46.1	33.8
Other non-current liabilities	9.5	9.7
Other current liabilities	13.9	16.1

At the end of August 2025, Gerresheimer took out two loans totaling EUR 200m for the early repayment of part of the bridge loan for the acquisition of Bormioli Pharma. The loans have a term until 2027 and 2028, respectively, and bear variable interest rates. The disbursements were made at the beginning of September 2025.

The change in net financial debt is mainly due to the utilization of bridge loan for the acquisition of Bormioli Pharma. This bridge loan has a term until September 2027.

Adjusted EBITDA leverage, i.e. the ratio of net financial debt to adjusted EBITDA for the last twelve months, was 4.15x as of the reporting date (November 30, 2024: 2.43x). Gerresheimer is therefore complying with its covenants.

Consolidated Income Statement

for the first nine months of the financial year 2025

In EUR k	Q3 2025	Q3 2024	9M 2025	9M 2024
Revenues	560,682	498,514	1,681,391	1,467,030
Cost of sales	-421,789	-350,677	-1,257,918	-1,040,945
Gross profit on sales	138,893	147,837	423,473	426,085
Selling and general administrative expenses	-100,982	-95,081	-309,456	-281,581
Research and development expenses	-5,565	-4,766	-14,840	-15,485
Other operating income	6,400	8,065	42,044	26,994
Other operating expenses	-31,364	-7,672	-68,051	-20,107
Operating income	7,382	48,383	73,170	135,906
Interest income	627	809	2,845	2,820
Interest expenses	-23,359	-15,458	-89,468	-43,160
Other financial result	337	1,419	1,900	3,666
Financial result	-22,395	-13,231	-84,723	-36,674
Income before income taxes	-15,013	35,152	-11,553	99,232
Income taxes	2,742	-7,485	-584	-25,208
Net income	-12,271	27,667	-12,137	74,024
Shareholders of Gerresheimer AG	-12,701	27,209	-13,691	72,679
Non-controlling interests	430	458	1,554	1,345
Basic and diluted earnings per share in euros	-0.37	0.79	-0.40	2.10

Consolidated Balance Sheet

as of August 31, 2025

In EUR k	Aug. 31, 2025	30.11.2024
Assets		
Intangible assets	1,711,129	1,241,173
Property, plant and equipment	1,815,121	1,506,265
Investment property	1,752	1,752
Investments accounted for using the equity method	19,469	20,513
Income tax receivables	1,596	4,038
Other financial assets	19,024	21,894
Other non-financial assets	3,617	3,844
Deferred tax assets	26,088	17,384
Non-current assets	3,597,796	2,816,863
Inventories	511,378	355,088
Trade receivables	267,672	310,641
Contract assets	23,465	13,191
Income tax receivables	13,177	8,388
Other financial assets	27,297	31,571
Other non-financial assets	100,115	83,903
Cash and cash equivalents	145,871	186,378
Non-current assets held for sale and discontinued operations	–	3,141
Current assets	1,088,975	992,301
Total assets	4,686,771	3,809,164
Equity and liabilities		
Subscribed capital	34,540	34,540
Capital reserve	778,475	778,475
Accumulated other comprehensive income	–145,389	–47,665
Retained earnings	734,246	746,212
Shareholders of Gerresheimer AG	1,401,872	1,511,562
Non-controlling interests	25,926	27,579
Equity	1,427,798	1,539,141
Provisions for pensions and similar obligations	95,539	98,758
Other provisions	12,397	12,736
Financial debt	1,705,667	916,651
Contract liabilities	75,767	73,048
Other financial liabilities	11,194	15,102
Other non-financial liabilities	56,854	51,882
Deferred tax liabilities	193,815	116,343
Non-current liabilities	2,151,233	1,284,520
Provisions for pensions and similar obligations	12,515	12,589
Other provisions	47,002	26,575
Financial debt	456,100	370,031
Trade payables and other liabilities	297,613	354,582
Contract liabilities	9,582	5,165
Income tax liabilities	17,418	16,227
Other financial liabilities	148,802	92,063
Other non-financial liabilities	118,708	108,271
Current liabilities	1,107,740	985,503
Total equity and liabilities	4,686,771	3,809,164

Consolidated Statement of Cash Flows

for the period from December 1, 2024, to August 31, 2025

In EUR k	9M 2025	9M 2024
Net income	-12,137	74,024
Income taxes	584	25,208
Financial result	84,723	36,674
Amortization/depreciation/impairment losses	200,936	146,517
Result of associated companies and other investment income	1,044	1,000
Change in provisions	6,380	-6,838
Result of disposals of non-current assets/liabilities	74	-712
Interest paid	-51,499	-30,457
Interest received	2,029	1,717
Income taxes paid	-30,206	-43,802
Income taxes received	3,073	13,048
Change in inventories	-67,331	-46,955
Change in trade receivables as well as contract assets	49,027	5,680
Change in trade payables and other liabilities as well as contract liabilities	-38,856	-36,280
Change in net working capital	-57,160	-77,555
Other non-cash-effective items	-28,050	-32,317
Cash flow from operating activities	119,791	106,506
Cash received from disposals of non-current assets	2,545	2,159
Cash paid for capital expenditure in intangible assets and property, plant and equipment	-250,413	-279,927
Payments received from government grants	9,280	18,424
Cash paid for capital expenditure in fully consolidated companies as well as other equity investments	-361,587	-9,331
Cash received in connection with divestments	5,821	-
Cash flow from investing activities	-594,354	-268,675
Dividend payments to third parties	-2,357	-45,431
Repayment of bonds (acquisition Bormioli Pharma)	-350,000	-
Raising of revolving credit facilities	177,000	329,963
Raising of credit facilities - bridge loan acquisition Bormioli Pharma	780,000	-
Repayment of revolving credit facilities	-75,000	-122,260
Repayment of credit facilities - bridge loan acquisition Bormioli Pharma	-55,000	-
Raising of other liabilities to banks	44,518	6,257
Repayment of other liabilities to banks	-63,270	-9,145
Cash paid for leases and installment purchase liabilities	-20,284	-16,181
Other issues from financing activities	2,519	106
Cash flow from financing activities	438,126	143,309
Changes in financial resources	-36,437	-18,860
Effect of exchange rate changes on financial resources	-12,902	-3,503
Financial resources at the beginning of the period	183,941	122,264
Financial resources at the end of the period	134,602	99,901
Components of the financial resources		
Cash and cash equivalents	145,871	109,450
Overdraft facilities	-11,269	-9,549
Financial resources at the end of the period	134,602	99,901

A consideration of EUR 389.6m was paid for the acquisition of Bormioli Pharma, as well as EUR 0.9m for the repayment of a shareholder loan. Cash and cash equivalents amounted to EUR 28.0m at the time of acquisition. The purchase price allocation had not yet been completed at the time of preparing the quarterly statement.

Reconciliation of Adjusted EBITDA to Net Income

for the first nine months of the financial year 2025

In EUR m	9M 2025	9M 2024	Change
Adjusted EBITDA			
Plastics & Devices	222.6	208.5	14.1
Adjusted EBITDA			
Primary Packaging Glass	127.2	119.7	7.5
Adjusted EBITDA			
Advanced Technologies	-12.3	-13.6	1.3
Adjusted EBITDA Corporate functions/consolidation	-23.6	-21.9	-1.7
Adjusted EBITDA	313.9	292.7	21.2
Depreciation/amortization and impairment losses	-150.8	-114.4	-36.4
Depreciation/amortization and impairment losses of fair value adjustments	-49.6	-28.6	-21.0
Exceptional income and expenses including restructuring	-40.3	-13.8	-26.5
Operating income	73.2	135.9	-62.7
Financial result	-84.7	-36.7	-48.0
Income taxes	-0.6	-25.2	24.6
Net income	-12.1	74.0	-86.1
Depreciation/amortization and impairment losses of fair value adjustments	49.6	28.6	21.0
Exceptional income and expenses including restructuring	40.3	13.8	26.5
Exceptional expenses on financial result	22.9	-	22.9
Tax effects	-28.4	-9.3	-19.1
Adjusted net income	72.3	107.1	-34.8
Non-controlling interests	1.6	1.4	0.2
Adjusted net income attributable to shareholders of Gerresheimer AG	70.8	105.7	-34.9
Adjusted EPS attributable to shareholders of Gerresheimer AG in euros	2.05	3.06	-1.01

Amortization and impairment losses of fair value adjustments related in the first nine months of the financial year 2025 to the subsequent measurement of intangible assets identified in connection with the acquisitions made in the period 2007 to 2018. At the beginning of the financial year 2025, Gerresheimer expanded the scope of depreciation, amortization and impairment losses of fair value adjustments to include depreciation, amortization and impairment losses related to the subsequent measurement of property, plant and equipment, in particular to properly reflect the significant effects of the purchase price allocation in connection with the acquisition of Bormioli Pharma. As a result, depreciation, amortization and impairment losses of fair value adjustments in the first nine months of the financial year 2025 derive from subsequent measurement of intangible assets and property, plant and equipment. The new definition applies for the first time to subsequent measurement in connection with the acquisition of Bormioli Pharma. Depreciation, amortization and impairment losses from subsequent

measurement of property, plant and equipment from acquisitions made in the period 2007 to 2018 are not adjusted.

In the first nine months of the financial year 2025, fair value adjustments were exclusively subject to scheduled depreciation and amortization.

Net income in the first nine months of 2025 was negatively impacted by exceptional income and expenses including restructuring totaling EUR 40.3m (prior-year period: EUR 13.8m), which are mainly attributable to the following special effects:

In EUR m	9M 2025	9M 2024	Change
Restructuring	16,660	1,227	15,433
Construction of new plants	11,248	4,674	6,574
Acquisition/divestment	6,864	871	5,993
Reorganization of divisions	3,262	1,711	1,551
Environmental issues	861	1,511	-650
Inflation compensation premium	-	2,991	-2,991
Other income and expenses	1,451	812	639
Exceptional income and expenses including restructuring	40,346	13,797	26,549

Restructuring expenses relate to initial measures in connection with structural and cost efficiency programmes in all business areas. Additional measures are planned for the remainder of the current financial year.

The one-off items in connection with acquisitions and divestment mainly comprise the expenses from the acquisition of Bormioli Pharma and the income from the sale of the remaining shares in Securetec Detektions-Systems AG, Neubiberg (Germany).

Expenses for new plant construction mainly comprise expenses in connection with the expansion of our plants in Skopje (Republic of North Macedonia), Peachtree (GA/USA) and Queretaro (Mexico).

The expenses for reorganization in the divisions mainly relate to measures in the Primary Packaging Glass division.

The one-off items from environmental issues largely comprise the expenses and insurance payments received in connection with the damage caused by Hurricane Helene at the Morganton site in the USA.

Additional Information

Financial Calendar

February 26, 2026	Publication Annual Report 2025
April 16, 2026	Publication Quarterly Statement for the 1 st Quarter 2026
June 3, 2026	Annual General Meeting 2026
July 14, 2026	Publication Half-year Financial Report 2026

Share Reference Data

ISIN	DE000AOLD6E6
German Securities Identification Number (WKN)	AOLD6E
Bloomberg ticker symbol	GXI
Reuters ticker symbol	GXIG.DE

Imprint

Publisher

Gerresheimer AG
Peter-Müller-Strasse 3
40468 Duesseldorf
Germany

Phone +49 211 6181-00
Fax +49 211 6181-295
E-Mail info@gerresheimer.com
www.gerresheimer.com

Disclaimer

This Quarterly Statement contains certain future-oriented statements. Future-oriented statements include all statements that do not relate to historical facts and events and contain future-oriented expressions such as "believe", "estimate", "assume", "expect", "forecast", "intend", "could" or "should" or expressions of a similar kind. Such future-oriented statements are subject to risks and uncertainties since they relate to future events and are based on the Company's current assumptions, which may not in the future take place or be fulfilled as expected. The Company points out that such future-oriented statements provide no guarantee for the future and that actual events, including the financial position and profitability of the Gerresheimer Group and developments in the economic and regulatory fundamentals, may vary substantially (particularly on the down side) from those explicitly or implicitly assumed or described in these statements. Even if the actual results for the Gerresheimer Group, including its financial position and profitability and the economic and regulatory environment, are in accordance with such future-oriented statements in this Quarterly Statement, no guarantee can be given that this will continue to be the case in the future.

Note regarding the rounding of figures

Due to the commercial rounding of figures and percentages, small deviations may occur.

Remarks on calculation

All changes in percent were calculated on a thousand-euro basis. Slight deviations may therefore occur when stating figures in millions of euros in the tables.

Note regarding the translation

This Quarterly Statement is the English translation of the original German version; in case of deviations between these two, the German version prevails.